The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.
Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.
Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Despite advancements in treatment strategies for mantle cell lymphoma, patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.
The combination of venetoclax and ibrutinib induced a 16-week complete response rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma.
Andre Goy, MD, discusses the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.
Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.